Alkermes plc (NASDAQ: ALKS) announced the initiation of its phase 3 Brilliance Studies program evaluating alixorexton for treating narcolepsy type ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE